CN117529313A - 固态形式的(s)-n-(3-(2-(((r)-1-羟基丙-2-基)氨基)-6-吗啉代吡啶-4-基)-4-甲基苯基)-3-(2,2,2-三氟乙基)吡咯烷-1-甲酰胺及其盐 - Google Patents

固态形式的(s)-n-(3-(2-(((r)-1-羟基丙-2-基)氨基)-6-吗啉代吡啶-4-基)-4-甲基苯基)-3-(2,2,2-三氟乙基)吡咯烷-1-甲酰胺及其盐 Download PDF

Info

Publication number
CN117529313A
CN117529313A CN202280044060.6A CN202280044060A CN117529313A CN 117529313 A CN117529313 A CN 117529313A CN 202280044060 A CN202280044060 A CN 202280044060A CN 117529313 A CN117529313 A CN 117529313A
Authority
CN
China
Prior art keywords
solid form
ray powder
powder diffraction
exhibits
compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202280044060.6A
Other languages
English (en)
Chinese (zh)
Inventor
史蒂芬·W·卡尔多
陶菲克·卡努尼
安德鲁·菲米斯特
贾亚钱德拉·P·雷迪
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pierre Fabre Medicament SA
Original Assignee
Jinnaite Biopharmaceutical Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Jinnaite Biopharmaceutical Co filed Critical Jinnaite Biopharmaceutical Co
Publication of CN117529313A publication Critical patent/CN117529313A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5355—Non-condensed oxazines and containing further heterocyclic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicinal Preparation (AREA)
CN202280044060.6A 2021-04-23 2022-04-21 固态形式的(s)-n-(3-(2-(((r)-1-羟基丙-2-基)氨基)-6-吗啉代吡啶-4-基)-4-甲基苯基)-3-(2,2,2-三氟乙基)吡咯烷-1-甲酰胺及其盐 Pending CN117529313A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163178752P 2021-04-23 2021-04-23
US63/178,752 2021-04-23
PCT/US2022/025815 WO2022226221A1 (en) 2021-04-23 2022-04-21 Solid state forms of (s)-n-(3-(2-(((r)-1-hydroxypropan-2-yl)amino)-6-morpholinopyridin-4-yl)-4-methylphenyl)-3-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and salts thereof

Publications (1)

Publication Number Publication Date
CN117529313A true CN117529313A (zh) 2024-02-06

Family

ID=83723159

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202280044060.6A Pending CN117529313A (zh) 2021-04-23 2022-04-21 固态形式的(s)-n-(3-(2-(((r)-1-羟基丙-2-基)氨基)-6-吗啉代吡啶-4-基)-4-甲基苯基)-3-(2,2,2-三氟乙基)吡咯烷-1-甲酰胺及其盐

Country Status (11)

Country Link
US (1) US20240208931A1 (https=)
EP (1) EP4326255A4 (https=)
JP (1) JP7825636B2 (https=)
KR (1) KR20240000540A (https=)
CN (1) CN117529313A (https=)
AU (1) AU2022261159A1 (https=)
BR (1) BR112023021916A2 (https=)
CA (1) CA3216258A1 (https=)
IL (1) IL307910A (https=)
MX (1) MX2023012521A (https=)
WO (1) WO2022226221A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7626910B2 (ja) 2019-10-24 2025-02-05 ピエール ファーブル メディカモン Ｒａｆキナーゼの阻害剤
WO2022081469A1 (en) 2020-10-12 2022-04-21 Kinnate Biopharma Inc. Inhibitors of raf kinases
BR112023021913A2 (pt) 2021-04-23 2024-01-16 Kinnate Biopharma Inc Tratamento de câncer com inibidor de raf

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9242969B2 (en) * 2013-03-14 2016-01-26 Novartis Ag Biaryl amide compounds as kinase inhibitors
UY36294A (es) * 2014-09-12 2016-04-29 Novartis Ag Compuestos y composiciones como inhibidores de quinasa
KR20210055042A (ko) * 2018-07-31 2021-05-14 오스칸 그룹 홀딩스 엘티디 “고체의 자가-유화 약학 조성물”
WO2020198058A1 (en) * 2019-03-22 2020-10-01 Kinnate Biopharma Inc. Inhibitors of raf kinases
TW202106684A (zh) * 2019-05-03 2021-02-16 美商奇奈特生物製藥公司 Raf激酶抑制劑
JP7626910B2 (ja) * 2019-10-24 2025-02-05 ピエール ファーブル メディカモン Ｒａｆキナーゼの阻害剤

Also Published As

Publication number Publication date
KR20240000540A (ko) 2024-01-02
IL307910A (en) 2023-12-01
AU2022261159A1 (en) 2023-11-23
JP2024517431A (ja) 2024-04-22
US20240208931A1 (en) 2024-06-27
BR112023021916A2 (pt) 2023-12-19
JP7825636B2 (ja) 2026-03-06
EP4326255A4 (en) 2025-03-12
CA3216258A1 (en) 2022-10-27
TW202309018A (zh) 2023-03-01
WO2022226221A1 (en) 2022-10-27
EP4326255A1 (en) 2024-02-28
MX2023012521A (es) 2023-12-15

Similar Documents

Publication Publication Date Title
CN117529313A (zh) 固态形式的(s)-n-(3-(2-(((r)-1-羟基丙-2-基)氨基)-6-吗啉代吡啶-4-基)-4-甲基苯基)-3-(2,2,2-三氟乙基)吡咯烷-1-甲酰胺及其盐
EP3938363A1 (en) Solid state forms of ripretinib
KR20170057441A (ko) Jak 억제제의 바이설페이트의 결정형 및 이의 제조방법
CN118201927A (zh) 戊二酸利那拉赞的盐酸盐的多晶型物
US10640487B2 (en) Solid state forms of Nilotinib salts
WO2019003249A1 (en) POLYMORPHIC FORMS OF BARICITINIB
TW201638090A (zh) 一種週期素依賴性蛋白激酶抑制劑的結晶形式及其製備方法
US20250059170A1 (en) Solid state forms of an fgfr inhibitor
CN106279127A (zh) 阿法替尼酸加成盐及其晶型、其制备方法及药物组合物
ES2651689T3 (es) Forma salina de alfa-6-mPEG6-O-hidroxicodona sólida como antagonista opioide y usos de la misma
TWI705065B (zh) 嗎啉衍生物的鹽及其晶型、其製備方法及藥物組成物、用途
TWI922665B (zh) (s)-n-(3-(2-(((r)-1-羥基丙-2-基)胺基)-6-嗎啉基吡啶-4-基)-4-甲基苯基)-3-(2,2,2-三氟乙基)吡咯啶-1-甲醯胺及其鹽之固態形式
WO2019205812A1 (zh) Acalabrutinib的新晶型及其制备方法和用途
HK40107041A (zh) 固态形式的(s)-n-(3-(2-(((r)-1-羟基丙-2-基)氨基)-6-吗啉代吡啶-4-基)-4-甲基苯基)-3-(2，2，2-三氟乙基)吡咯烷-1-甲酰胺及其盐
US20240270733A1 (en) Hydrate form of lazertinib mesylate, preparation method thereof and use thereof
US20220389022A1 (en) Solid forms of ponatinib hydrochloride and process thereof
JP2025525475A (ja) Ｎ－［４－（４－［［２－（ジメチルアミノ）エチル］アミノ］－３－メチル－１Ｈ－ピラゾロ［３，４－ｄ］ピリミジン－６－イル）－２－フルオロフェニル］－２，５－ジフルオロベンゼンスルホンアミドの塩及びそれらの結晶形態
WO2025085791A1 (en) Crystalline forms of mrtx0902
EP3517529B1 (en) Salt of quinazoline derivative, preparation method therefor and application thereof
KR20060093564A (ko) 무수 시부트라민 말산염 및 이의 제조 방법
HK1213549B (en) Solid salt form of alpha-6-mpeg6-o-hydroxycodone as opioid agonists and uses thereof

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
TA01 Transfer of patent application right
TA01 Transfer of patent application right

Effective date of registration: 20240909

Address after: Laval, France

Applicant after: PIERRE FABRE MEDICAMENT

Country or region after: France

Address before: California, USA

Applicant before: Jinnaite biopharmaceutical Co.

Country or region before: U.S.A.

REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40107041

Country of ref document: HK